However, after adjusting for different clinical variables, patients with HER2-low status had worse DFS than patients with HER2-negative tumors37 These data indirectly support our results suggesting that the immune system of ER-low and –intermediate BC statuses of tumors behave similarly to that of primary TNBC.36 The gene discussed is ERBB2; the disease is breast cancer.